Neurocrine Biosciences continues strong with Ingrezza and Crenessity growth, plus a promising pipeline in MDD and ...

CSI Synod condemns unjust arrest of nuns in Chhattisgarh, demands release and end to religious intimidation. Solidarity rally ...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly, we'd ...

Cardinal Health is preparing to announce its second-quarter results next month, and analysts are anticipating an earnings ...

Discover key insights from Neurocrine Biosciences' Q2 2025 earnings, featuring record INGREZZA growth, CRENESSITY's rapid adoption, and strategic ...

Investors in Cardinal Health, Inc. (Symbol: CAH) saw new options become available today, for the September 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance.

Recent discussions on X about Cardinal Health (CAH) have centered around the company’s upcoming fourth-quarter and year-end financial results for fiscal year 2025, set to be released on August ...

CVS Health Corporation CVS posted second-quarter 2025 adjusted earnings per share (EPS) of $1.81, down 1.1% year over year.

Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.